<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03650946</url>
  </required_header>
  <id_info>
    <org_study_id>201508052MIND</org_study_id>
    <nct_id>NCT03650946</nct_id>
  </id_info>
  <brief_title>Clinical Application of 68Ga-PSMA PET in Prostate Cancer</brief_title>
  <official_title>Clinical Application of 68Ga-PSMA PET in Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prostate cancer is the 7th leading cause of cancer death for men in Taiwan. It is important&#xD;
      to identify the extent of disease extent to deliver adequate treatment, either for primary&#xD;
      staging or in recurrence. However, conventional imaging techniques including computed&#xD;
      tomography, bone scintigraphy, and immunoscintigraphy with 111In-capromab pendetide are not&#xD;
      sensitive or specific enough to detect metastatic or recurrent disease. Although more widely&#xD;
      applied, magnetic resonance still relies on size and shape criteria. 68Ga-PSMA is a new novel&#xD;
      positron emission radiotracer which several preliminary data has shown to be effective of&#xD;
      detecting recurrent or metastatic prostate cancer. These studies are confined to a small&#xD;
      retrospective European population. In this study we aim to synthesize the novel tracer, find&#xD;
      the usefulness of 68Ga-PSMA PET in detecting prostate cancer, including primary staging and&#xD;
      recurrence, explore the relationship between imaging and clinical parameters, and seek the&#xD;
      possibility of 68Ga-PSMA PET to predict tumor nature and prognosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prostate cancer is the 7th leading cause of cancer death for men in Taiwan. It is important&#xD;
      to identify the extent of disease extent to deliver adequate treatment, either for primary&#xD;
      staging or in recurrence. However, conventional imaging techniques including computed&#xD;
      tomography, bone scintigraphy, and immunoscintigraphy with 111In-capromab pendetide are not&#xD;
      sensitive or specific enough to detect metastatic or recurrent disease. Although more widely&#xD;
      applied, magnetic resonance still relies on size and shape criteria. 68Ga-PSMA is a new novel&#xD;
      positron emission radiotracer which several preliminary data has shown to be effective of&#xD;
      detecting recurrent or metastatic prostate cancer. These studies are confined to a small&#xD;
      retrospective European population. In this study we aim to synthesize the novel tracer, find&#xD;
      the usefulness of 68Ga-PSMA PET in detecting prostate cancer, including primary staging and&#xD;
      recurrence, explore the relationship between imaging and clinical parameters, and seek the&#xD;
      possibility of 68Ga-PSMA PET to predict tumor nature and prognosis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Anticipated">August 2018</start_date>
  <completion_date type="Anticipated">July 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnostic accuracy</measure>
    <time_frame>1 year</time_frame>
    <description>initial staging compared to pathology, clinical and follow-up result</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>men with high or intermediate risk localized disease who are about to undergo definitive surgery or radiotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>men with rising PSA after local definitive treatments</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <description>m0CRPC with a PSA &gt;1.0 or 2.0</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Ga-68 PSMA PET</intervention_name>
    <description>Ga-68 PSMA PET</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Histologically confirmed prostate cancer&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed prostate cancer&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with known malignancy in other organs.&#xD;
&#xD;
          -  Patients with severe claustrophobia or unstable vital sigh&#xD;
&#xD;
          -  Other serious comorbidities evaluated by primary investigator&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ching Chu Lu</last_name>
      <phone>+886-2-23123456</phone>
      <phone_ext>65477</phone_ext>
      <email>kelvinlu@ntu.edu.tw</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>August 27, 2018</study_first_submitted>
  <study_first_submitted_qc>August 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 29, 2018</study_first_posted>
  <last_update_submitted>August 27, 2018</last_update_submitted>
  <last_update_submitted_qc>August 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate cancer</keyword>
  <keyword>Ga-68 PSMA PET</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

